113 related articles for article (PubMed ID: 35947048)
1. Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
Patel R; Hovstadius M; Kier MW; Moshier EL; Zimmerman BS; Cascetta K; Jaffer S; Sparano JA; Tiersten A
Cancer; 2022 Oct; 128(20):3602-3609. PubMed ID: 35947048
[TBL] [Abstract][Full Text] [Related]
2. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.
Wang J; Chen H; Koenig J; Wu Y; Bedrosian I; Arun B; Ding Q; Khazai L; Resetkova E; Huo L; Sneige N; Albarracin C
Breast Cancer Res Treat; 2024 Jan; 203(1):73-83. PubMed ID: 37751078
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
[TBL] [Abstract][Full Text] [Related]
4. Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX® test data: a retrospective multicenter study in Japan.
Tsuchida Y; Niikura N; Chishima T; Mizuno M; Kawate T; Fuchikami H; Miyoshi Y; Sakai T; Kotani H; Kondo N; Hayashi N
Breast Cancer; 2024 May; 31(3):401-408. PubMed ID: 38451415
[TBL] [Abstract][Full Text] [Related]
5. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
6. Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
Licata L; De Sanctis R; Vingiani A; Cosentini D; Iorfida M; Caremoli ER; Sassi I; Fernandes B; Gianatti A; Guerini-Rocco E; Zambelli C; Munzone E; Simoncini EL; Tondini C; Gentilini OD; Zambelli A; Pruneri G; Bianchini G
Breast Cancer Res Treat; 2024 May; 205(1):39-48. PubMed ID: 38265569
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.
Ahn SG; Bae SJ; Yoon C; Cha YJ; Lee HW; Lee SA; Jeong J
PLoS One; 2017; 12(11):e0187679. PubMed ID: 29117208
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system.
Shim VC; Baker RJ; Jing W; Puentes R; Agersborg SS; Lee TK; GoreaI W; Achacoso N; Lee C; Villasenor M; Lin A; Kapali M; Habel LA
Breast Cancer Res Treat; 2024 Jan; 203(2):281-289. PubMed ID: 37847456
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
Mutai R; Barkan T; Moore A; Sarfaty M; Shochat T; Yerushalmi R; Stemmer SM; Goldvaser H
Breast; 2021 Dec; 60():62-69. PubMed ID: 34481367
[TBL] [Abstract][Full Text] [Related]
10. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX
Aktas B; Bankfalvi A; Heubner M; Kimmig R; Kasimir-Bauer S
Mol Clin Oncol; 2013 Nov; 1(6):1049-1054. PubMed ID: 24649291
[TBL] [Abstract][Full Text] [Related]
12. Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age.
Williams AD; Pawloski KR; Wen HY; Sevilimedu V; Thompson D; Morrow M; El-Tamer M
Breast Cancer Res Treat; 2022 Dec; 196(3):565-570. PubMed ID: 36269526
[TBL] [Abstract][Full Text] [Related]
13. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Tyburski H; Karakas C; Finkelman BS; Turner BM; Zhang H; Hicks DG
Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
[TBL] [Abstract][Full Text] [Related]
14. Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.
Mohamed A; Olsson LT; Geradts J
Breast Cancer Res Treat; 2023 Oct; 201(3):447-460. PubMed ID: 37453958
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Oncotype DX Recurrence Score by Evaluating the Peritumoral Tumor Budding in Early-stage Breast Carcinoma.
Chu J; DO J; DO SI; Kim HS
Anticancer Res; 2023 Dec; 43(12):5563-5572. PubMed ID: 38030177
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours.
Bernhardt SM; Dasari P; Glynn DJ; Woolford L; Moldenhauer LM; Walsh D; Townsend AR; Price TJ; Ingman WV
BMC Cancer; 2021 Jun; 21(1):736. PubMed ID: 34174867
[TBL] [Abstract][Full Text] [Related]
17. Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.
Loggie J; Barnes PJ; Carter MD; Rayson D; Bethune GC
Breast; 2024 Jun; 75():103715. PubMed ID: 38520994
[TBL] [Abstract][Full Text] [Related]
18. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
[No Abstract] [Full Text] [Related]
19. Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective.
Peters AL; Hall PS; Jordan LB; Soh FY; Hannington L; Makaranka S; Urquhart G; Vallet M; Cartwright D; Marashi H; Elsberger B
Breast; 2024 Jun; 75():103728. PubMed ID: 38657322
[TBL] [Abstract][Full Text] [Related]
20. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
Mooghal M; Khan MAA; Samar MR; Shaikh H; Valimohammad AT; Idrees R; Abdul Rashid Y; Sattar AK
Breast Cancer (Auckl); 2024; 18():11782234241255211. PubMed ID: 38779417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
